Chronic DiseaseMURDOCKNCT01708408
The MURDOCK Study Registry and Biorepository Horizon 1.5
An observational study of Chronic Disease and Healthy Volunteers, run by Duke University at 1 site in United States.
Trial summary
The MURDOCK Study Community Registry and Biorepository (Horizon 1.5) aims to create a large-scale community registry and biorepository that can be used as a vehicle for future health services, epidemiologic, clinical trials and other omics-related research. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Chronic Disease, Healthy Volunteers
- What is being tested?
- Biomarker studies
- How many people
- 50,000 participants
- Where
- 1 siteUnited States
- Study dates
- Feb 2009to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The Community Registry and Biorepository is designed to create a community registry and biorepository populated by approximately 50,000 residents of Cabarrus County and/or the city of Kannapolis in North Carolina.
Who may be able to join
- A resident of Cabarrus County and/or the city of Kannapolis (and surrounding regions) for 6 or more months of the year
- At least 18 years of age
- Able to understand and give written informed consent, or have a legal guardian or caregiver present to give informed consent by proxy (assent from a participant between ages 12-18 will be obtained when their parent or legal guardian consents on their behalf).
- Willing and able to participate in all 5 components of the registry and biorepository as described above in Section III
Who cannot join
- 1. There are no exclusions to participation if all inclusion criteria have been met.
Trial locations and contacts
1 site in 1 country.
United States1 site
Duke Clinical Translational Science Institute-MURDOCK Study
Kannapolis, North Carolina, 28081
About this study
Official title: Measurement to Understand Reclassification of Disease of Cabarrus/Kannapolis The MURDOCK Study Registry and Biorepository Horizon 1.5
The MURDOCK Study Community Registry and Biorepository (Horizon 1.5) aims to create a large-scale community registry and biorepository that can be used as a vehicle for future health services, epidemiologic, clinical trials and other omics-related research.
Read the detailed description
The MURDOCK Study Community Registry and Biorepository's activities include enrolling approximately 50,000 participants who live in Cabarrus County and/or Kannapolis, North Carolina. Participants must consent to (1) use of the data provided by the participant through completion of the Participant Registry Questionnaire for epidemiologic population characterization, (2) annual contact to update their MURDOCK Horizon 1.5 database record, (3) release of their medical information, including but not limited to demographic information, problem lists, medications, social and family history, and results of laboratory and other testing modalities from pre-existing paper or electronic health records or electronic health records that may become available in the future, (4) provision of a blood and urine sample, and (5) contact up to four times/year to request participation in additional research studies.
- Conditions
- Chronic Disease, Healthy Volunteers
- Being tested
- Biomarker studies
- Keywords
- biorepository, biobank, registry, community, biospecimens, volunteers, chronic disease, longitudinal, blood, electronic health records, follow-up
- Medical subject headings
- Chronic Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biomarker studiesGenetic
| Study group | Role | What they receive |
|---|---|---|
| community | Not described Receives: Genetic: Biomarker studies |
What is being measured
The primary outcome is the main question the study is designed to answer.
The MURDOCK Study Registry and Biorepository Horizon 1.5
To provide information for large-scale epidemiologic and clinical translational research and the research infrastructure to identify specific phenotypes and outcomes to improve medicine
Measured: Upto 119 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Oct 2012 (estimated)
- Study startFeb 2009
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Chronic DiseaseStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 50,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Kristin M Newby, MD, Principal investigator, Duke University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01708408
- Sponsor's protocol ID
- Pro00011196
- Acronym
- MURDOCK
- Status last verified
- Feb 2026
- First submitted
- 15 Oct 2012
- Last updated
- 4 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Tenenbaum JD, Christian V, Cornish MA, Dolor RJ, Dunham AA, Ginsburg GS, Kraus VB, McHutchison JG, Nahm ML, Newby LK, Svetkey LP, Udayakumar K, Califf RM. The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. Am J Transl Res. 2012;4(3):291-301. Epub 2012 Jul 23.
PubMed 22937207
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Measurement to Understand Reclassification of Disease of Cabarrus/Kannapolis The MURDOCK Study Registry and Biorepository Horizon 1.5
- ClinicalTrials.gov ID
- NCT01708408
- Acronym / sponsor ID
- MURDOCK / Pro00011196
- Conditions
- Chronic Disease, Healthy Volunteers
- Keywords
- biorepository, biobank, registry, community, biospecimens, volunteers, chronic disease, longitudinal
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 50,000 participants (estimated)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Study start
- Feb 2009 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 17 Oct 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The MURDOCK Study Community Registry and Biorepository (Horizon 1.5) aims to create a large-scale community registry and biorepository that can be used as a vehicle for future health services, epidemiologic, clinical trials and other omics-related research.
Detailed description
The MURDOCK Study Community Registry and Biorepository's activities include enrolling approximately 50,000 participants who live in Cabarrus County and/or Kannapolis, North Carolina. Participants must consent to (1) use of the data provided by the participant through completion of the Participant Registry Questionnaire for epidemiologic population characterization, (2) annual contact to update their MURDOCK Horizon 1.5 database record, (3) release of their medical information, including but not limited to demographic information, problem lists, medications, social and family history, and results of laboratory and other testing modalities from pre-existing paper or electronic health records or electronic health records that may become available in the future, (4) provision of a blood and urine sample, and (5) contact up to four times/year to request participation in additional research studies.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| community | – | Genetic: Biomarker studies |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The Community Registry and Biorepository is designed to create a community registry and biorepository populated by approximately 50,000 residents of Cabarrus County and/or the city of Kannapolis in North Carolina.
Key inclusion criteria (4 listed)
- A resident of Cabarrus County and/or the city of Kannapolis (and surrounding regions) for 6 or more months of the year
- At least 18 years of age
- Able to understand and give written informed consent, or have a legal guardian or caregiver present to give informed consent by proxy (assent from a participant between ages 12-18 will be obtained when their parent or legal guardian consents on their behalf).
- Willing and able to participate in all 5 components of the registry and biorepository as described above in Section III
Key exclusion criteria (1 listed)
- 1. There are no exclusions to participation if all inclusion criteria have been met.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biomarker studies | Genetic | community |
Primary outcome
The MURDOCK Study Registry and Biorepository Horizon 1.5
Time frame: Upto 119 months
To provide information for large-scale epidemiologic and clinical translational research and the research infrastructure to identify specific phenotypes and outcomes to improve medicine
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2026.
- Background: PubMed 22937207Tenenbaum JD, Christian V, Cornish MA, Dolor RJ, Dunham AA, Ginsburg GS, Kraus VB, McHutchison JG, Nahm ML, Newby LK, Svetkey LP, Udayakumar K, Califf RM. The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. Am J Transl Res. 2012;4(3):291-301. Epub 2012 Jul 23.
- MURDOCK Study websiteLink provided by the sponsor.
Related trials for Chronic Disease
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Not yet recruiting
Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy
Cerebral Palsy
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kristin M Newby, MD principal investigator
Duke University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Disease and Healthy Volunteers, run by Duke University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 4 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The MURDOCK Study Registry and Biorepository Horizon 1.5 (time frame: Upto 119 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01708408, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2026.